# clm_55A89BC77171

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: quarterly_research_and_development  
value: 843,800,000 United States dollar  
valid_from: 2022-03-31  
valid_to: 2022-06-30  
published: 2022-05-04  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_DC9A1606D340  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals quarterly research and development: 843,800,000 United States dollar", as of 2022-03-31 (until 2022-06-30). Claim clm_55A89BC77171, https://asof.is/claim/clm_55A89BC77171, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2022, filed 2022-05-04  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000180422022000015/0001804220-22-000015-index.htm (primary, SEC EDGAR 10-Q Q1 FY2022, published 2022-05-04)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_research_and_development | 665,400,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_55A89BC77171](/claim/clm_55A89BC77171.md) | [clm_D602B5B0E5C5](/claim/clm_D602B5B0E5C5.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.